Clinical Trials Logo

Clinical Trial Summary

Osteochondral defects (OCD) of the talus are pathologic lesions of the talar cartilage and its subchondral bone and might severely deteriorate the quality of life. For the treatment of multiple and/or large talar OCDs and in patients with failed previous surgical treatment the Ankle Spacer was developed. Six patients are included in a prospective clinical and radiological study with a follow-up of two years.


Clinical Trial Description

One surgeon in the investigator's center implanted 10 Ankle Spacers between April 2018 and October 2020. The average age was 41.7 years (20 - 70 years). All patients get a standard followed-up at 6 weeks, 12 weeks. After the first four patients, all following patients are enrolled in a prospective study and where followed up after 1 and 2 years additionally. The American Orthopaedic Foot and Ankle Society (AOFAS) Score, the Foot and Ankle Outcome Score (FAOS), the European Foot and Ankle Score (EFAS), the Visual Analogue Scale (VAS) for pain are collected. Radiographic parameters such as implant loosening, cystic changes, lateral/medial prominence of the implant, congruency to the talar rounding, progression of osteoarthritis or bone ware of the tibia plafond are recorded. The Ankle Spacer is a one-piece implant system that replaces the articulating upper talus surface of the tibio-talar joint, and offers several implant sizes in order to fit to the different talus sizes. It is anatomically designed to the native upper talus surface to provide an optimal fit to the distal articular surface. It has a rough titanium plasma spray (TPS) coated under surface with two posts and spikes for implant fixation. The rough surface enables secondary fixation by means of bone ingrowth and the spikes at the posterior part of the prosthesis allowing for optimal adherence of the implant and for minimal iatrogenic damage upon fixation. By these means, the anatomical situation and the natural congruency of the ankle joint are mirrored to an optimal extent. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04297449
Study type Observational
Source Hannover Medical School
Contact
Status Completed
Phase
Start date January 18, 2019
Completion date September 3, 2021

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01458782 - ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee N/A
Active, not recruiting NCT02771496 - Osteochondritis Dissecans of Knee Prospective Cohort
Completed NCT02397278 - Intra Articular Injections With Platelet Rich Plasma in Patients With Juvenile Osteochondritis Dissecans of the Knee N/A
Active, not recruiting NCT01347892 - DeNovo NT Ankle LDC Study N/A
Recruiting NCT01409447 - Repair of Articular Osteochondral Defect N/A
Active, not recruiting NCT03656185 - Elbow Arthroscopy Data Analysis
Completed NCT01471236 - Evaluation of the Agili-C Biphasic Implant in the Knee Joint N/A
Enrolling by invitation NCT01455987 - Osteochondritis Dissecans of the Knee N/A
Recruiting NCT01159899 - Transplantation of Bone Marrow Stem Cells Stimulated by Proteins Scaffold to Heal Defects Articular Cartilage of the Knee Phase 0
Terminated NCT00881023 - Cartilage Autograft Implantation System (CAIS) for the Repair of Knee Cartilage Through Cartilage Regeneration N/A
Recruiting NCT04364334 - Knee Registry (Knieregister)
Recruiting NCT01498029 - Knee Articular Cartilage Repair: Cartilage Autograft Implantation System Versus Conventional Microfracture Phase 3
Completed NCT03452098 - Post-Operative Rehabilitation of Knee Osteochondral Defect: A Case Series
Suspended NCT02664337 - Conjoint Analysis of Patient Preferences in Joint Interventions N/A
Active, not recruiting NCT01329445 - DeNovo NT Longitudinal Data Collection (LDC) Knee Study N/A
Completed NCT02993510 - A Randomized Controlled Trial Comparing Chondro-Gide® to Microfracture Alone for Treatment of Knee Cartilage Defects. Phase 3
Recruiting NCT01694823 - Safety and Efficacy Study of Cells Sheet-Autologous Chondrocyte Implantation to Treat Articular Cartilage Defects Phase 1/Phase 2
Withdrawn NCT01283737 - Use of Demineralised Bone Matrix (DBX) in Osteochondritis Dissecans (OCD) Phase 4